Global X Dow 30 Covered Call & Growth ETF(DYLG.US)

Company Encyclopedia
View More
name
Global X Dow 30 Covered Call & Growth ETF
DYLG.US
News
View More

Jamie Dimon says U.S. economy is resilient as JPMorgan Chase earnings beat expectations

JPMorgan Chase CEO Jamie Dimon stated that the U.S. economy is resilient, as the bank's fourth-quarter earnings exceeded expectations. The bank reported a 7% drop in profit to $13 billion, but revenue rose 7% to $46.8 billion. Despite a significant increase in provisions for credit losses, JPMorgan's earnings per share of $5.23 surpassed analyst forecasts. The bank's stock rose 1% in premarket trading, reflecting a 31% increase over the past year. Dimon noted strong consumer spending and healthy business conditions.

Dow Jones·
US
JPM
-1.43%
Dow Jones·
US
JPM
-1.43%

Amgen says MariTide helped trial patients maintain weight loss

Amgen's experimental obesity drug MariTide has shown promising results in maintaining weight loss in mid-stage trials. The drug, which also lowered blood sugar levels in diabetes patients, was well-tolerated during a second year of treatment. CEO Bob Bradway announced these findings at the J.P. Morgan Healthcare Conference. The company plans to start future trials with lower doses to minimize gastrointestinal side effects. MariTide's unique mechanism involves activating GLP-1 receptors while blocking GIP receptors, setting it apart from other popular weight-loss drugs.

Reuters·
US
AMGN
-0.17%
Reuters·
US
AMGN
-0.17%

Amgen Says 24-Week Study Of Monthly Maritide In People With Type 2 Diabetes Showed Robust, Clinically Meaningful Reduction In Both HBA1C, Weight

Amgen Inc announced that a 24-week study of its monthly Maritide treatment for Type 2 diabetes demonstrated significant reductions in both HbA1c levels and weight. The company noted that a large majority of participants in a subsequent 52-week extension study maintained their weight loss with lower or quarterly doses of the drug. The second year of Maritide treatment was well tolerated, showing a very low incidence of nausea and vomiting, with no new safety concerns reported.

Reuters·
US
AMGN
-0.17%
Reuters·
US
AMGN
-0.17%

Amgen's MariTide phase 2 study shows 'meaningful' reduction in blood sugar, weight

Jan 12 (Reuters) - Amgensaid on Monday a 24-week study of monthly doses of its experimental obesity drug MariTide in people with type 2 diabetes showed “robust and clinically meaningful” reduction in both blood sugar and weight.In a 52-week extension study, a large majority of participants who received a lower monthly dose or a quarterly dose maintained the weight loss achieved during the initial phase 2 trial, the company said.

Reuters·
US
AMGN
-0.17%
Reuters·
US
AMGN
-0.17%

Amgen: Second year of Maritide treatment very well tolerated including at quarterly doses, with very low incidence of nausea, vomiting & no new safety signals observed

Amgen: Second year of Maritide treatment very well tolerated including at quarterly doses, with very low incidence of nausea, vomiting & no new safety signals observed

marketscreener·
US
AMGN
-0.17%
marketscreener·
US
AMGN
-0.17%
© 2026 Longbridge｜Disclaimer